After three decades watching global central banks navigate the fine line between policy caution and market expectation, one truth always stands:In Japan, silence often speaks louder than change. The Bank of Japan (BOJ) left interest rates unchanged at 0.5%, but reaffirmed its readiness to tighten if economic conditions evolve as projected.For markets, that was enough...
After three decades following global monetary cycles, I’ve learned this:Markets don’t react to policy — they react to the direction of conviction. This week, the Bank of Japan (BOJ) held short-term rates steady at 0.5%, reaffirming its cautious pledge to tighten only if the economy performs in line with projections.For investors, the message is clear...
Over three decades in finance, I’ve seen one constant evolution —the boundary between public and private capital keeps fading. This week, Morgan Stanley announced its acquisition of EquityZen, a leading private shares platform that connects investors with pre-IPO companies. It’s more than just another acquisition.It’s a strategic statement — one that signals how Wall Street...
After three decades in investment strategy, I’ve learned this:Markets don’t punish weakness — they punish surprise. That’s exactly what happened yesterday when Chipotle’s stock plunged nearly 19%, wiping out $9 billion in market value after its third downward sales forecast revision this year. Behind this single-day drop lies a larger narrative — one that cuts...
After three decades observing the intersection of finance and sustainability, one thing is clear: ESG strategy has entered a new era of recalibration. This week, State Street Global Advisors, the world’s fourth-largest asset manager overseeing more than $5.4 trillion, announced that it would withdraw its U.S. operations from the Net Zero Asset Managers (NZAM) initiative,...
Eli Lilly (LLY.N) announced a $1.2 billion investment to expand its manufacturing site in Carolina, Puerto Rico, as part of a broader $50 billion U.S. manufacturing initiative aimed at boosting domestic production capacity and mitigating potential tariff risks. The upgraded facility will produce Orforglipron, Lilly’s upcoming oral weight-loss treatment expected to be submitted for global...